Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | phosphodiesterase 4D, cAMP-specific | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0112 | 0.6744 | 0.6285 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0051 | 0.1234 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0147 | 1 | 1 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0051 | 0.1234 | 0.5 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0147 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0051 | 0.1234 | 0.5 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0051 | 0.1234 | 0.5 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0051 | 0.1234 | 0.5 |
Trypanosoma brucei | trypanothione reductase | 0.0147 | 1 | 1 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0112 | 0.6744 | 0.6285 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0051 | 0.1234 | 0.5 |
Schistosoma mansoni | camp-specific 35-cyclic phosphodiesterase | 0.0112 | 0.6744 | 0.6285 |
Plasmodium vivax | glutathione reductase, putative | 0.0147 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0112 | 0.6744 | 0.2752 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0051 | 0.1234 | 0.5 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0051 | 0.1234 | 0.1234 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0098 | 0.5507 | 0.4875 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0147 | 1 | 1 |
Leishmania major | trypanothione reductase | 0.0147 | 1 | 1 |
Brugia malayi | Probable 3',5'-cyclic phosphodiesterase R153.1, putative | 0.0098 | 0.5507 | 0.5507 |
Treponema pallidum | NADH oxidase | 0.0051 | 0.1234 | 0.5 |
Loa Loa (eye worm) | glutathione reductase | 0.0147 | 1 | 1 |
Giardia lamblia | CAMP-specific 3,5-cyclic phosphodiesterase 4B | 0.0112 | 0.6744 | 1 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0051 | 0.1234 | 0.5 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0147 | 1 | 1 |
Toxoplasma gondii | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein | 0.0112 | 0.6744 | 0.6285 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0112 | 0.6744 | 0.6285 |
Plasmodium falciparum | thioredoxin reductase | 0.0147 | 1 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0147 | 1 | 1 |
Plasmodium falciparum | glutathione reductase | 0.0147 | 1 | 1 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0112 | 0.6744 | 0.6285 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0147 | 1 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0147 | 1 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0051 | 0.1234 | 0.5 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0098 | 0.5507 | 0.4875 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0147 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 82 nM | In vitro inhibition of phosphodiesterase (PDE IV) from guinea pig macrophages. | ChEMBL. | 9871693 |
IC50 (binding) | = 82 nM | In vitro inhibition of phosphodiesterase (PDE IV) from guinea pig macrophages. | ChEMBL. | 9871693 |
Ki (binding) | = 476 nM | Affinity for phosphodiesterase (PDE IV) in guinea pig brain membrane using [3H]-rolipram displacement. | ChEMBL. | 9871693 |
Ki (binding) | = 476 nM | Affinity for phosphodiesterase (PDE IV) in guinea pig brain membrane using [3H]-rolipram displacement. | ChEMBL. | 9871693 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.